The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
The bioavailability (BA) of a tripeptide protease inhibitor, KNI-272, which has a strong pharmacological potential for treating human immunodeficiency virus type 1 (HIV-1), has been studied in beagle dogs by administering several oral dosage forms. The tested dosage forms were form 1, plain gelatin capsules; forms 2 and 3, gelatin capsules of which the inner and outer surfaces were coated with 7G ethylcellulose (EC, 30 mu m thickness) and an enteric coating material, hydroxypropyl methylcellulose phthalate (HP-55), respectively; and form 4, gelatin capsules of which the inner surface is coated with 10G EC (60 mu m thickness). The difference between forms 2 and 3 was the amount of citric acid contained in the capsule, namely 100 mg in form 2 and 200 mg in form 3. One hundred milligrams of KNI-272 was placed in each capsule after being dissolved with propylene glycol (PG). These capsules were used to deliver KNI-272 to the stomach for form 1, to the upper part of the small intestine for forms 2 and 3, and to the middle part of the small intestine for form 4. As a reference, 50.0 mg of KNI-272 was administered to the same dogs by intravenous (IV) infusion for 15 min. By measuring the plasma drug levels with the HPLC method, BAs were estimated for each test dosage form. Form 1 showed the highest BA of 26 center dot 2 +/- 7 center dot 0% (mean +/- SE), though the other capsules showed BAs of approximately 10%, namely 6 center dot 6 +/- 0 center dot 4% for form 2, 10 center dot 3 +/- 1 center dot 1% for form 3 and 14 center dot 2 +/- 1 center dot 0% for form 4. Therefore, as the site where KNI-272 is released from the capsule becomes higher, the BA increases. In addition, as the amount of citric acid contained in a capsule increases, the BA value tends to increase. These results suggest that KNI-272 is stable and not extensively hydrolysed in the gut after oral administration, that the dissolution process into GI fluids is important for the BA of KNI-272, and that the most appropriate absorption site of KNI-272 in dogs is the duodenum. The potential of this new tripeptide compound as an orally active anti-AIDS drug has been confirmed.
Department of Pharmaceutics and Pharmacokinetics, Kyoto Pharmaceutical University, Yamashina-ku, Japan.
A
A
Kiriyama
M
M
Sugahara
Y
Y
Yoshikawa
Y
Y
Kiso
K
K
Takada
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D004285:Dogs; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D009842:Oligopeptides / Q000493:pharmacokinetics*; D051381:Rats; D013045:Species Specificity
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; C077822:kynostatin 272